NewsRamp provides syndicated and curated news distribution and marketing services for major newswires.
August 1, 2024 — CareWork Inc. achieves over 500% revenue growth in 2024, demonstrating its commitment to innovation and outstanding customer service in the senior living and long-term care sector.
August 1, 2024 — iuvo announces the launch of iuvo Secure AI Host, a solution that empowers life science companies, data-intensive industries, and any organization that wants to tightly control AI, to utilize advanced AI capabilities securely on-premises or in a private cloud environment.
July 31, 2024 — InMed Pharmaceuticals reports positive results from a long-term study of INM-901, showing potential breakthroughs in Alzheimer’s disease treatment. The study confirms improvements in cognitive function, memory, and locomotor activity, addressing the critical need for effective treatments.
July 31, 2024 — SenesTech (NASDAQ: SNES) is featured on The GotStock Podcast, with president and CEO Joel Fruendt discussing the company's innovative approach to managing animal-pest populations through fertility control. The discussion highlights the effectiveness and sustainability of SenesTech's product, ContraPest(R), and its potential impact in improving overall pest management.
July 31, 2024 — Zynex Inc CEO Thomas Sandgaard reveals record growth in Q2 results and future innovations, demonstrating strong financial performance and innovation efforts in medical device market.
July 31, 2024 — Syra Health Corp. secures $5.8M contract to train healthcare workers in Indiana, demonstrating commitment to improving healthcare through innovative technology and services.
July 31, 2024 — Mainz Biomed applies for FDA breakthrough status for its colorectal cancer test, combining traditional testing with mRNA analysis and AI algorithms. If granted, this could revolutionize early detection and accessibility of screening, potentially saving countless lives.
July 31, 2024 — GVT achieves TX-RAMP Level 2 Certification, demonstrating commitment to data security and privacy. Learn more about the FAMCare platform and GVT's software solutions.
July 30, 2024 — CNS Pharmaceuticals (NASDAQ: CNSP) enters into an exclusive license agreement with Cortice Biosciences Inc. to acquire intellectual property rights to TPI 287, a potential treatment for glioblastoma multiforme. The agreement demonstrates the company's commitment to addressing the urgent need for effective therapies for this aggressive form of brain cancer.
July 30, 2024 — Acarix CEO announces the company's trading on the OTCQB Market in the US, showcasing its non-invasive solution for ruling out coronary artery disease and its focus on saving healthcare costs and driving commercial success.
July 30, 2024 — Citius Pharmaceuticals is close to commercializing two groundbreaking healthcare products, potentially offering alternative treatments for serious medical conditions. Additionally, the company's strategic moves, such as spinning out its oncology unit, have the potential to provide significant value for shareholders and access to new opportunities in the healthcare sector.
July 30, 2024 — Pancreatic cancer incidence on the rise, with promising treatment in development by Oncolytics Biotech to improve survival rates and impact patients' lives. Learn more about the development of pelareorep and its potential in pancreatic cancer treatment.
July 29, 2024 — Clene Inc. is gearing up for Phase 3 trials of CNM-Au8 for ALS and MS, showcasing its potential to revolutionize the treatment of neurodegenerative diseases. The company's innovative gold nanocrystal technology could have a profound impact on the lives of millions.
July 29, 2024 — Clene Inc. is making significant strides in the development of innovative treatments for neurodegenerative diseases, with a focus on ALS and MS. Learn more about their groundbreaking approach and potential impact.
July 29, 2024 — AGC Biologics achieves a new commercial milestone for regulatory compliance in 2024 at its Seattle Campus, with two products approved for commercial production. This showcases the company's commitment to quality and regulatory compliance, benefiting the pharmaceutical industry and patients seeking new treatments.
July 29, 2024 — Best Growth Stocks issues a comprehensive analysis of Tivic Health Systems, providing insights into potential catalysts and growth strategy, and offering investors direct access to CEOs of promising, publicly-traded companies.
July 29, 2024 — 16th Annual Sickle Cell Disease Educational Summit: Join us for a four-day event addressing all aspects of sickle cell disease and trait awareness and education. Foster empowerment through knowledge-sharing and community engagement.
July 28, 2024 — Dr. Robert Corkern launches scholarship for future rural doctors, providing support for aspiring medical professionals committed to enhancing healthcare in underserved rural communities.
July 26, 2024 — CNS Pharmaceuticals, a biopharmaceutical company, will present an abstract at the 2024 SNO/ASCO CNS Cancer Conference. The event highlights the development of potential treatments for aggressive brain cancer.
July 26, 2024 — PaxMedica prepares NDA submission to FDA for suramin and pivotal meeting for PAX-101, demonstrating commitment to advancing healthcare solutions and addressing crucial public health needs.